Mild Cognitive Impairment Clinical Trials 2024

What are the top hospitals conducting mild cognitive impairment research?

The pursuit of understanding and treating mild cognitive impairment, a condition characterized by subtle memory and thinking difficulties, is gaining traction in top hospitals across the globe. In Berkeley, California, the University of California takes the lead with four ongoing clinical trials dedicated to studying this condition. While they may not have any previous trials on record, their commitment to investigating mild cognitive impairment offers hope for future breakthroughs. Similarly, at the Centre for Addiction and Mental health in Toronto, researchers are actively conducting four clinical trials focused on mild cognitive impairment but have yet to embark on historical studies.

Meanwhile, in Ann Arbor at the University of Michigan Medical Center and Winter Park's Conquest Research facility,vital contributions are being made as well. Both centers currently engage in three active clinical trials exploring mild cognitive impairment. The University of Michigan has already completed one trial since its inception in 2023 - marking an exciting milestone just a few years into their research efforts. Likewise, Conquest Research also launched its first recorded trial in 2023 alongside Butler Hospital located within Providence city; both sharing equal accomplishment with two active ongoing investigations each.

These hospitals' dedication demonstrates a shared commitment to unraveling the mysteries surrounding mild cognitive impairment while working towards effective prevention or treatment strategies that can improve the lives of those affected by these memory-related challenges. As we collectively strive toward advancing our knowledge and interventions around this complex condition it becomes evident that every step taken brings us closer to unlocking potential solutions for individuals worldwide who live with mild cognitive impairments

Which are the best cities for mild cognitive impairment clinical trials?

When it comes to mild cognitive impairment clinical trials, several cities have emerged as leaders in research and development. Toronto, Ontario leads the way with 17 active trials investigating treatments like tDCS + CR, BIIB080, and Experimental: 1.0 mg/kg XPro1595. New york City follows closely behind with 11 ongoing studies focused on interventions such as Home-based MT through Supervised, Supported Singing (H3S), Home-based walking exercise, and Valacyclovir. Chicago also plays a significant role with 8 active trials exploring strategies like Home-based walking exercise and Low level of signal manipulation using the MagVenture MagProX100 stimulator. Winter Park, Florida contributes to the field with 7 active trials studying Donanemab Dose Level 4, BIIB080, and MK-2214. Lastly, Decatur in Georgia rounds out the list with 6 active trials examining options including Donanemab Dose Level 4, MK-2214,and SAGE-718 in hopes of advancing our understanding and treatment of mild cognitive impairment.

Which are the top treatments for mild cognitive impairment being explored in clinical trials?

Researchers are actively exploring various treatments for mild cognitive impairment (MCI) in clinical trials. Among the top contenders is cognitive training, which has shown promising results. With two active trials and two all-time MCI trials since its first listing in 2015, cognitive training offers hope for individuals experiencing MCI symptoms. These trials aim to assess the effectiveness of this intervention in improving cognition and potentially slowing down or preventing further decline in those affected by MCI. As researchers delve deeper into understanding MCI, they strive to find innovative ways to enhance cognitive function and improve the quality of life for those living with this condition.

What are the most recent clinical trials for mild cognitive impairment?

Recent clinical trials offer promising prospects for individuals with mild cognitive impairment, a condition characterized by memory and cognitive decline. One notable study involves the administration of psilocybin to participants with amnestic mild cognitive impairment, aiming to explore its potential therapeutic effects in mitigating symptoms. Additionally, inhalational anesthesia has been investigated as a treatment option in this population, seeking to evaluate its impact on cognition. Another trial examines the efficacy of precision medicine in Group A patients diagnosed with mild cognitive impairment while CP-CGMH focuses on assessing the safety and tolerability of an experimental treatment approach. Lastly, Donanemab Dose Level 4 is being evaluated for its effectiveness in managing mild cognitive impairment symptoms through Phase 3 testing. These studies offer hope for improved interventions and enhanced quality of life for those affected by this challenging condition.

What mild cognitive impairment clinical trials were recently completed?

Recently completed clinical trials have focused on mild cognitive impairment, a condition that can precede the development of dementia. Notable trials include one sponsored by the National Institute on Aging which investigated the effects of an experimental drug in managing cognitive decline. Another trial conducted by a team at Johns Hopkins University explored non-pharmacological interventions to improve cognitive function in individuals with mild cognitive impairment. These studies contribute invaluable insights into potential treatments and strategies for addressing this challenging condition and offer hope for those affected.